Drug profile

The FDA adverse-event record for Vitmain B

73 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Vitmain B. See the species affected, top reactions, and outcomes below.

73
adverse-event reports
43.8%
death-coded share
Dog
most-reported species
25
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
73
Total Reports
32
Deaths Reported
43.8%
Death Rate

Active Ingredients

Vitmain B

Administration Routes

UnknownSubcutaneousIntravenousOral

Species Affected

Dog 37
Cat 32
Cattle 4

Most Affected Breeds

Domestic Shorthair 21
Retriever - Labrador 10
Domestic Longhair 6
Aberdeen Angus 2
Cat (unknown) 2
Mixed (Dog) 2
Cat (other) 2
Chihuahua 2
Setter - Irish Red 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 25
Vomiting 24
Anorexia 21
Death by euthanasia 18
Death 14
Anaemia NOS 13
Elevated alanine aminotransferase (ALT) 13
Weight loss 12
Diarrhoea 12
Other abnormal test result NOS 11
Abnormal ultrasound finding 9
Not eating 9

Outcome Breakdown

Ongoing
35 (47.3%)
Euthanized
18 (24.3%)
Died
14 (18.9%)
Recovered/Normal
4 (5.4%)
Outcome Unknown
3 (4.1%)

Vitmain B Adverse Event Insights

73 reports name Vitmain B; 32 recorded a death outcome (43.8% of reported events, not a population-level mortality rate). Active ingredient: Vitmain B. Administration routes: Unknown, Subcutaneous, Intravenous, Oral.

By species: Dog (37 reports), Cat (32 reports), Cattle (4 reports). By breed: Domestic Shorthair (21), Retriever - Labrador (10), Domestic Longhair (6).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (25), Vomiting (24), Anorexia (21), Death by euthanasia (18). Outcome, 74 coded reports: Ongoing leads at 47.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.